Non-alcoholic fatty liver disease (NAFLD) represents a significant and growing public health concern in the global medical community. Characterized by the accumulation of excess fat in the liver of individuals who consume little to no alcohol, NAFLD encompasses a disease spectrum from simple steatosis to non-alcoholic steatohepatitis (NASH), fibrosis, and cirrhosis.
Afflicting approximately 25% of the global population, NAFLD prevalence is escalating in tandem with the rising incidence of obesity and type 2 diabetes. The prevalence is highest in the Middle East and South America and lowest in Africa. However, the disease is not confined to these regions and is an escalating concern worldwide.
The pathogenesis of NAFLD is multifaceted, involving genetic predisposition, insulin resistance, and metabolic syndrome. The 'two-hit' hypothesis has been widely accepted to explain the progression from simple steatosis to NASH. The first 'hit' involves the accumulation of triglycerides in the liver, while the second 'hit' leads to inflammation, cell death, and fibrosis.
Proactive management of NAFLD is critical for preventing disease progression and complications. Lifestyle modifications including diet changes and physical activity remain first-line interventions. Pharmacotherapy may be considered in patients with NASH and significant fibrosis, particularly those at high risk of progression. Emerging therapies targeting various aspects of NAFLD pathophysiology are under investigation.
NAFLD is a significant global health burden with a complex pathophysiology. Proactive identification and management are crucial to mitigate disease progression and associated complications. As healthcare professionals, maintaining an up-to-date understanding of this disease and its management strategies is critical to improving patient outcomes.
1.
Is Laughter Good for Blood Glucose Control?
2.
NIH research cuts leave cancer patient facing hard choice
3.
Scientists Employ Technology to Identify Plagiarism and Forgeries in Published Studies.
4.
Ruxolitinib Reduces Acute GVHD in Transplant Patients
5.
Retired Olympic athletes at greater risk of skin cancer and osteoarthritis, research reveals
1.
The Revolutionary Treatment of Hodgkin's Lymphoma: A New Hope for the Future
2.
Unlocking the Key to Treating Lymphoma: New Innovations in Cancer Research
3.
Aging of Bone-Marrow Immune Niches: Mechanisms, Clinical Impact, and Therapeutic Horizons
4.
Biomarkers of Marrow Regenerative Capacity Following Repeated Hematopoietic Stress
5.
Consensus Recommendations for Healthy Hematologic Aging
1.
International Conference on Innovations in Critical Care for Oncology and Cardiology
2.
International Conference on Oncology, Cardiology and Critical Care Policy
3.
International Conference on Oncology, Cancer Prevention and Public Health
4.
International Conference on Cancer Nursing and Rehabilitation Strategies
5.
International Conference on Best Practices in Oncology, Cardiology and Critical Care
1.
Virtual Case Study on Pedal Edema and Triple Vessel Disease - An Initiative by Hidoc Dr.
2.
Current Scenario of Blood Cancer- Genomic Testing & Advancement in Diagnosis and Treatment
3.
Unmet Needs in ALK Positive NSCLC- The Challenges in the Current Care
4.
Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part V
5.
Updates on the First Line Management of ALK+ NSCLC
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation